$8.4 M

UNUM Therapeutics Revenue FY, 2017
UNUM Therapeutics Revenue growth (FY, 2016 - FY, 2017), %32%
UNUM Therapeutics Net income (FY, 2017)-25.5 M
UNUM Therapeutics EBIT (FY, 2017)-26.2 M
UNUM Therapeutics Cash, 31-Dec-201728.3 M

UNUM Therapeutics Income Statement

Annual

USDFY, 2015FY, 2016FY, 2017

Revenue

3.0m6.4m8.4m

Revenue growth, %

113%32%

R&D expense

6.9m22.0m29.8m

General and administrative expense

2.7m3.4m4.7m

Operating expense total

9.6m25.4m34.5m

EBIT

(6.6m)(19.1m)(26.2m)

EBIT margin, %

(221%)(300%)(313%)

Interest income

265.0k386.0k

Net Income

(6.6m)(18.1m)(25.5m)

UNUM Therapeutics Balance Sheet

Annual

USDFY, 2016FY, 2017

Cash

41.3m28.3m

Accounts Receivable

928.0k830.0k

Prepaid Expenses

296.0k513.0k

Current Assets

69.7m42.4m

PP&E

4.6m4.1m

Total Assets

75.6m49.1m

Accounts Payable

1.5m1.3m

Current Liabilities

8.7m11.2m

Total Liabilities

23.2m20.8m

Common Stock

10.0k10.0k

Preferred Stock

77.1m77.2m

Additional Paid-in Capital

1.2m2.5m

Retained Earnings

(25.8m)(51.3m)

Total Equity

(24.7m)(48.8m)

Financial Leverage

-3.1 x-1 x

UNUM Therapeutics Cash Flow

Annual

USDFY, 2015FY, 2016FY, 2017

Net Income

(6.6m)(18.1m)(25.5m)

Depreciation and Amortization

179.0k830.0k1.2m

Accounts Receivable

(294.0k)(634.0k)98.0k

Accounts Payable

705.0k389.0k(31.0k)

Cash From Operating Activities

17.7m(18.6m)(25.8m)

Purchases of PP&E

(2.0m)(3.3m)(912.0k)

Cash From Investing Activities

(3.2m)(30.4m)13.5m

Cash From Financing Activities

70.8m(40.0k)(729.0k)

Net Change in Cash

85.2m(49.1m)(13.1m)

UNUM Therapeutics Ratios

USDY, 2017

Revenue/Employee

146.2k

Financial Leverage

-1 x
Report incorrect company information

UNUM Therapeutics Operating Metrics

Mar, 2018

Phase I Trials Products

3

Preclinical Phase Products

1
Report incorrect company information